Pharsight

1. List of Sivextro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676	CUBIST PHARMS LLC	Oxazolidinone derivatives	Feb, 2028 (4 years from now)
US7816379	CUBIST PHARMS LLC	Oxazolidinone derivatives	Jun, 2028 (5 years from now)
US10442829	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (6 years from now)
US9624250	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (6 years from now)
US8426389	CUBIST PHARMS LLC	Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Dec, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (6 years from now)
US10065947	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (6 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 20, 2019
New Patient Population (NPP)	Jun 19, 2023
Generating Antibiotic Incentives Now (GAIN)	Jun 20, 2024

NCE-1 date: 2023-06-21

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: TABLET;ORAL